Drug & intervention

omalizumab

RxCUI 302379

Clinical trials52
Recruiting2
Related conditions19
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Omalizumab

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy. Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to the membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. In 1987, Tanox filed its first patent application on the anti-IgE drug candidate. Omalizumab was approved for medical use in the United States in June 2003, and authorized in the European Union in October 2005.

Read on Wikipedia ↗ Wikidata Q415392 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarNCT07425639 · 2025-10-02
RECRUITING
Omalizumab Before Onset of ExacerbationsNCT05332067 · 2022-05-01
RECRUITING
Trial of JYB1904 in Patients With Allergic AsthmaNCT06438757 · 2024-06-19
COMPLETED
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsNCT04998604 · 2021-09-27
COMPLETED
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.NCT05424523 · 2021-02-25
COMPLETED
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and SafetyNCT04778137 · 2020-12-01
COMPLETED
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic AsthmaNCT04195958 · 2020-11-30
TERMINATED
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United StatesNCT05157087 · 2020-03-01
COMPLETED
Preventing Asthma in High Risk KidsNCT02570984 · 2018-11-27
ACTIVE_NOT_RECRUITING
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".NCT04585997 · 2018-11-03
UNKNOWN
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma PatientsNCT02654145 · 2016-03-17
COMPLETED
Sputum-derived Cellular Targets After Xolair (Omalizumab)NCT02658877 · 2016-01-01
TERMINATED
Omalizumab for LupusNCT01716312 · 2014-01-08
COMPLETED
Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated AsthmaNCT01912872 · 2013-11-11
TERMINATED
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)NCT01922037 · 2013-06-19
COMPLETED
Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in BasophilsNCT02023151 · 2013-02-01
COMPLETED
Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With RhinovirusNCT02388997 · 2013-02-01
COMPLETED
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaNCT01716754 · 2012-12-01
COMPLETED
A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaNCT01703312 · 2012-11-01
COMPLETED
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese ChildrenNCT01328886 · 2011-03-01
COMPLETED
Safety and Efficacy Study of Omalizumab to Treat Allergic AsthmaNCT01976208 · 2010-12-01
COMPLETED
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 TherapyNCT01202903 · 2010-09-01
COMPLETED
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)NCT01155700 · 2010-06-01
COMPLETED
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term TherapyNCT01125748 · 2010-05-01
COMPLETED
Omalizumab in Non-atopic AsthmaNCT01113437 · 2010-04-01
UNKNOWN
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled AsthmaNCT01007149 · 2009-09-01
COMPLETED
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic AsthmaNCT00870584 · 2009-03-01
COMPLETED
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic AsthmaNCT00567476 · 2007-11-01
COMPLETED
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic AsthmaNCT00434434 · 2007-10-01
COMPLETED
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced AsthmaNCT00495612 · 2007-09-01
COMPLETED
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate AsthmaNCT00546143 · 2007-07-01
COMPLETED
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.NCT00500539 · 2007-07-01
COMPLETED
The Effect of Xolair (Omalizumab) on Allergy Blood CellsNCT00657891 · 2007-03-01
COMPLETED
Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and AsthmaNCT01393340 · 2006-12-01
COMPLETED
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic AsthmaNCT00454051 · 2006-12-01
COMPLETED
Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With OmalizumabNCT00287378 · 2006-03-01
TERMINATED
Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic RhinoconjunctivitisNCT00396409 · 2006-02-01
COMPLETED
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic AsthmaNCT00267202 · 2005-12-01
COMPLETED
A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced AsthmaNCT00242359 · 2005-11-01
WITHDRAWN
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic AsthmaNCT00264849 · 2005-11-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.